Surmodics, Inc.

NasdaqGS:SRDX Stock Report

Market Cap: US$614.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surmodics Future Growth

Future criteria checks 3/6

Surmodics is forecast to grow earnings and revenue by 74.1% and 3.3% per annum respectively while EPS is expected to grow by 74.2% per annum.

Key information

74.1%

Earnings growth rate

74.17%

EPS growth rate

Medical Equipment earnings growth16.4%
Revenue growth rate3.3%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Nov 2025

Recent future growth updates

Recent updates

Analysis Article • Jun 06

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Surmodics, Inc. ( NASDAQ:SRDX ) shares have continued their recent momentum with a 29% gain in the last month alone...
Analysis Article • May 30

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

Surmodics, Inc. ( NASDAQ:SRDX ), is not the largest company out there, but it received a lot of attention from a...
Analysis Article • May 02

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
Analysis Article • Sep 17

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Jun 26

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc. ( NASDAQ:SRDX ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Jun 22

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Surmodics fair value estimate is US$41.07 Surmodics' US$30.10...
Analysis Article • May 14

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Apr 17

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Those holding Surmodics, Inc. ( NASDAQ:SRDX ) shares would be relieved that the share price has rebounded 36% in the...
Analysis Article • Feb 03

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

The results at Surmodics, Inc. ( NASDAQ:SRDX ) have been quite disappointing recently and CEO Gary Maharaj bears some...
Analysis Article • Jan 08

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Oct 17

Surmodics gets additional $125M in credit facility

Surmodics (NASDAQ:SRDX) has entered into a new, five-year credit agreement with MidCap Financial, comprised of up to $100M in term loans and a $25M revolving credit facility. The Company drew $25M on the term loan and $5M on the revolving credit facility at close. These proceeds were partially used to retire the company’s existing $25M revolving credit facility with Bridgewater Bank, of which $10M was outstanding. Upon closing, the company’s cash balance increased by $19.5M. Additional draws on the term loan may be made in $10M minimum increments, up to a total of $75M through December 31, 2024. A second tranche of up to $25M may be available through December 31, 2024 at MidCap’s option.  The credit agreement calls for interest-only payments on the term loan over the first four years, which can be extended to five years if certain criteria are met. The revolving credit facility matures in five years. Company expects total interest expense and fees under the credit agreement to be ~$3.4M in fiscal 2023.

Earnings and Revenue Growth Forecasts

NasdaqGS:SRDX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2027130411N/A1
9/30/2026122-103N/A2
9/30/2025118-20-6N/A2
6/30/2025121-18-4-2N/A
3/31/2025122-20-7-5N/A
12/31/2024125-14-21N/A
9/30/2024126-12-30N/A
6/30/2024121-1-6-2N/A
3/31/2024143142326N/A
12/31/202313861013N/A
9/30/2023133-2811N/A
6/30/2023131-2347N/A
3/31/2023103-36-26-23N/A
12/31/2022102-32-25-21N/A
9/30/2022100-27-21-17N/A
6/30/202298-13-19-14N/A
3/31/202297-10-13-8N/A
12/31/20211062813N/A
9/30/20211054915N/A
6/30/202110421116N/A
3/31/202110772024N/A
12/31/2020951611N/A
9/30/20209511014N/A
6/30/202010382025N/A
3/31/20201017713N/A
12/31/20191006613N/A
9/30/2019100818N/A
6/30/2019922-60N/A
3/31/201990-2N/A3N/A
12/31/201887-2N/A28N/A
9/30/201881-4N/A34N/A
6/30/201878-2N/A36N/A
3/31/2018741N/A37N/A
12/31/2017720N/A13N/A
9/30/2017734N/A14N/A
6/30/2017716N/A14N/A
3/31/2017739N/A20N/A
12/31/20167310N/A21N/A
9/30/20167110N/A25N/A
6/30/2016719N/A22N/A
3/31/2016679N/A18N/A
12/31/20156411N/A16N/A
9/30/20156212N/A15N/A
6/30/20156013N/A18N/A
3/31/20155913N/A19N/A
12/31/20145812N/A19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: SRDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SRDX is expected to become profitable in the next 3 years.

Revenue vs Market: SRDX's revenue (3.3% per year) is forecast to grow slower than the US market (10.3% per year).

High Growth Revenue: SRDX's revenue (3.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SRDX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/20 03:23
End of Day Share Price 2025/11/18 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Surmodics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Michael PetuskyBarrington Research Associates, Inc.
Jan WaldBenchmark Company